目的:调查男性前列腺癌的终生风险。
方法:在2015年9月至2020年6月期间,在G_TEBORG-2试验中邀请男性进行前列腺特异性抗原(PSA)筛查的调查研究。
方法:哥德堡地区的38775名男性,瑞典,被邀请进行PSA测试并参与了一项调查。
方法:17980名男性参加了PSA测试,其中13189人完成了调查。此外,1264名男性仅回答了调查。
方法:在进行PSA测试之前,男性回答了一项电子调查,并以视觉模拟量表估计他们接受前列腺癌诊断的终生风险为0%至100%。
方法:主要结果是中位终生风险估计,与Wilcoxon检验相比,预期终生风险为20%(基于G_TEBORG-1试验).次要结果是在多变量线性回归模型中确定与风险估计相关的因素:先前的前列腺检查,家族史,体育锻炼,健康饮食,合并症,酒精消费,吸烟,教育水平,婚姻状况,泌尿症状和勃起功能障碍。
结果:在PSA测试的男性中,估计前列腺癌的终生风险中位数为30%(IQR19%至50%),与预期风险相比,估计高出10个百分点(p<0.001)。前列腺癌家族史,中度至重度泌尿系症状和轻度至中度勃起功能障碍与>5个百分点的高风险估计相关.对于未经PSA测试的男性也获得了类似的结果。
结论:大多数男性高估了他们的前列腺癌风险,这强调了向他们提供关于前列腺癌的准确信息的重要性。
背景:ISRCTN94604465。
OBJECTIVE: Investigating men\'s perceived lifetime risk of prostate cancer.
METHODS: Survey-based
study to men invited for prostate-specific antigen (PSA) screening in the GÖTEBORG-2
trial between September 2015 and June 2020.
METHODS: 38 775 men in the Gothenburg area, Sweden, were invited for PSA-testing and participated in a survey.
METHODS: 17 980 men participated in PSA-testing, of whom 13 189 completed the survey. In addition, 1264 men answered the survey only.
METHODS: Before having the PSA-test, men answered an electronic survey and estimated their lifetime risk of receiving a prostate cancer diagnosis on a visual analogue scale from 0% to 100%.
METHODS: The primary outcome was the median lifetime risk estimation, which was compared with Wilcoxon test to an anticipated lifetime risk of 20% (based on GÖTEBORG-1
trial). The secondary outcome was to determine factors associated with risk estimation in a multivariable linear regression model: previous prostate examination, family history, physical exercise, healthy diet, comorbidity, alcohol consumption, smoking, education level, marital status, urinary symptoms and erectile dysfunction.
RESULTS: Among PSA-tested men, the median estimated lifetime risk of prostate cancer was 30% (IQR 19% to 50%), corresponding to a 10 percentage-points higher estimation compared with the anticipated risk (p<0.001). Family history of prostate cancer, moderate to severe urinary symptoms and mild to moderate erectile dysfunction were associated with >5 percentage-points higher risk estimation. Similar results were obtained for non-PSA-tested men.
CONCLUSIONS: Most men overestimated their prostate cancer risk which underscores the importance of providing them accurate information about prostate cancer.
BACKGROUND: ISRCTN94604465.